I 
117TH CONGRESS 
2D SESSION 
H. R. 7308 
To direct the Inspector General of the Department of Health and Human 
Services to investigate and report on the Vaccine Adverse Event Report-
ing System, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 31, 2022 
Mrs. GREENE of Georgia introduced the following bill; which was referred to 
the Committee on Energy and Commerce, and in addition to the Com-
mittee on Ways and Means, for a period to be subsequently determined 
by the Speaker, in each case for consideration of such provisions as fall 
within the jurisdiction of the committee concerned 
A BILL 
To direct the Inspector General of the Department of Health 
and Human Services to investigate and report on the 
Vaccine Adverse Event Reporting System, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Justice for Vaccine 
Victims Act of 2022’’. 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
SEC. 2. INVESTIGATION ON VACCINE ADVERSE EVENT RE-
PORTING SYSTEM. 
(a) IN GENERAL.—The Inspector General of the De-
partment of Health and Human Services shall investigate 
the Vaccine Adverse Event Reporting System of the Cen-
ters for Disease Control and Prevention and Food and 
Drug Administration. 
(b) REQUIRED QUESTIONS.— 
(1) INDIVIDUALS.— 
(A) In conducting the investigation under 
subsection (a), the Inspector General of the De-
partment of Health and Human Services shall 
ask every individual who reported an adverse 
event to a COVID–19 vaccine at a minimum 
the following questions: 
(i) Which COVID–19 vaccine did you 
receive? 
(ii) Which vaccine did you receive as 
a booster shot? 
(iii) Do you have any allergies or pre-
existing conditions? 
(iv) Was the adverse event mild, such 
as minor pain or swelling, or severe, such 
as leading to hospitalization, disability, or 
death? 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
(v) Can you describe in detail the 
symptoms of the adverse event? 
(vi) In detail, can you describe any 
health problems you believe were caused by 
the adverse event? 
(vii) Are you aware of any other indi-
viduals within your community who had a 
similar adverse event? 
(viii) When receiving a vaccination did 
you notice anything suspicious regarding 
how the vaccination was administered? 
(ix) How soon after the adverse event 
did you report it to the Vaccine Adverse 
Event Reporting System? 
(x) Did you seek compensation for the 
adverse 
event 
through 
the 
Counter-
measures Injury Compensation Program? 
(xi) Would you be willing to testify 
under oath to a congressional committee? 
(B) If an individual described in subpara-
graph (A) is deceased, the Inspector General of 
the Department of Health and Human Services 
shall ask one or more of the individual’s imme-
diate family members to answer (on the individ-
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
ual’s behalf) the questions listed in subpara-
graph (A). 
(2) MANUFACTURERS.—In conducting the in-
vestigation under subsection (a), the Inspector Gen-
eral of the Department of Health and Human Serv-
ices shall ask each manufacturer of a COVID–19 
vaccine that is distributed in the United States, at 
a minimum, the following questions and requests: 
(A) What are the ingredients in your 
COVID–19 vaccine or vaccines distributed in 
the United States? 
(B) Can you provide all information relat-
ing to your manufacturing methods and your 
data on the stability and safety of the product? 
(C) What is the address of each of your lo-
cations involved in the manufacture of the vac-
cines? 
(D) Did you include labeling of the vaccine 
or vaccines containing a specific statement de-
scribing how suspected adverse events can be 
reported? 
(E) Can you provide substantive evidence 
you have followed all Food and Drug Adminis-
tration guidance regarding product safety? 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
(F) How many adverse events did you re-
port to the Vaccine Adverse Event Reporting 
System pursuant to section 2125 of the Public 
Health Service Act (42 U.S.C. 300aa–25) or 
other applicable law? 
(G) Are you conducting your own internal 
review of any adverse events caused by the vac-
cine or vaccines? 
(H) Are you ensuring that all public state-
ments regarding vaccine safety are accurate? 
(I) Are you limiting reporting data regard-
ing adverse events? 
(J) Would you be willing to direct rep-
resentatives to testify under oath to a congres-
sional committee? 
(3) HEALTH CARE PROVIDERS.—In conducting 
the investigation under subsection (a), the Inspector 
General of the Department of Health and Human 
Services shall ask a representative sample of health 
care providers, at a minimum, the following ques-
tions: 
(A) How many adverse events did you re-
port to the Vaccine Adverse Event Reporting 
System pursuant to section 2125 of the Public 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
Health Service Act (42 U.S.C. 300aa–25) or 
other applicable law? 
(B) What kind of compensation does your 
facility receive for vaccine administration and 
from which source or sources? 
(C) Is your facility keeping a record of any 
increase in hospitalization rates for individuals 
with adverse events following vaccination? 
(D) How many severe adverse events has 
your facility encountered? 
(E) How many mild adverse events has 
your facility encountered? 
(F) Has your facility determined if adverse 
events are caused by an immune response to 
the vaccine? 
(G) Is your facility keeping a record of any 
problems with vaccine administration? 
(H) Is your facility keeping a record of all 
breakthrough cases of COVID–19 in fully vac-
cinated patients? 
(I) Has your facility terminated any health 
care professionals who are opposed to vaccine 
mandates or who have raised questions regard-
ing adverse events? 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
(J) Would you be willing to direct rep-
resentatives of your facility to testify under 
oath to a congressional committee? 
(c) REPORTS.— 
(1) REPORT ON VAERS.— 
(A) IN
GENERAL.—Not later than 3 
months after the date of enactment of this Act, 
the Inspector General of the Department of 
Health and Human Services shall— 
(i) complete the investigation under 
subsection (a); and 
(ii) publish a report on the results of 
such investigation. 
(B) CONTENTS.—The report under sub-
paragraph (A)(ii) shall include the following: 
(i) A list of all reported COVID–19 
vaccine related deaths and injuries in 
chronological order. 
(ii) Transcripts of all interviews con-
ducted by the Inspector General pursuant 
to this section with an individual described 
in subsection (b)(1), a manufacturer de-
scribed in subsection (b)(2), or a health 
care provider described in subsection 
(b)(3). 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
(iii) A list of recommendations on how 
the Centers for Disease Control and Pre-
vention and the Food and Drug Adminis-
tration can strengthen the Vaccine Adverse 
Event Reporting System to be a more reli-
able method of obtaining information 
about adverse events. 
(iv) A determination on whether the 
Centers for Disease Control and Preven-
tion or the Food and Drug Administration 
is hiding data regarding adverse events. 
(v) A determination on whether the 
Food and Drug Administration is sup-
pressing data on the effectiveness of 
monoclonal antibodies that are used to 
treat COVID–19. 
(vi) Recommendations on further ac-
tions the Congress can take when con-
ducting oversight regarding data collection 
by the Centers for Disease Control and 
Prevention and the Food and Drug Admin-
istration. 
(vii) A determination on whether ad-
verse events are common or rare following 
administration of a COVID–19 vaccine. 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
(viii) A determination of any causal 
relationship between any COVID–19 vac-
cine and specific adverse events using clin-
ical, laboratory, or epidemiologic evidence. 
(ix) A determination on whether ad-
verse events are intrinsic to the COVID–19 
vaccine (meaning provoked by the immune 
response caused by the vaccine) or related 
to faulty production or administration of 
the COVID–19 vaccine. 
(2) REPORT ON INVESTIGATION.— 
(A) IN
GENERAL.—Not later than 6 
months after publishing the report required by 
paragraph (1)(A)(ii), the Inspector General of 
the Department of Health and Human Services 
shall submit to the relevant congressional com-
mittees a report on the implementation of this 
section. 
(B) CONTENTS.—The report under sub-
paragraph (A) shall— 
(i) specify, of the amount authorized 
by subsection (c)(1) to be appropriated to 
carry out this section, the total amount ob-
ligated and expended; and 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
(ii) describe how such amount was 
used. 
(d) SUBPOENA POWER.—The Inspector General of 
the Department of Health and Human Services may, pur-
suant to authorities vested in the Inspector General by 
other applicable law, issue subpoenas requiring the attend-
ance and testimony of witnesses and the production of any 
evidence relating to any matter under investigation pursu-
ant to this section. 
(e) AUTHORIZATION OF APPROPRIATIONS.— 
(1) IN GENERAL.—To carry out this section, 
there is authorized to be appropriated $100,000,000 
for the period beginning on the date of enactment of 
this Act and ending on the date of submission of the 
report required by subsection (b)(2). 
(2) OFFSET.— 
(A) REPEAL OF DEDUCTION FOR CERTAIN 
STATE AND LOCAL, ETC., TAXES OF INDIVID-
UALS.—Section 164(b)(6) of the Internal Rev-
enue Code of 1986 is amended by— 
(i) striking ‘‘and before January 1, 
2026—’’ and all that follows through ‘‘a 
separate return).’’ and inserting ‘‘para-
graphs (1), (2), and (3) of subsection (a) 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
and paragraph (5) of this subsection shall 
not apply.’’; and 
(ii) by striking ‘‘FOR TAXABLE YEARS 
2018 THROUGH 2025’’ in the heading there-
of. 
(B) EFFECTIVE DATE.—The amendments 
made by this paragraph shall apply to taxable 
years beginning after the date of the enactment 
of this Act. 
SEC. 3. TERMINATION OF COVID–19 PUBLIC HEALTH EMER-
GENCY DECLARATION UNDER PUBLIC READI-
NESS 
AND 
EMERGENCY 
PREPAREDNESS 
(PREP) ACT. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services shall— 
(1) not later than 3 months after the date of 
enactment of this Act, terminate the public health 
emergency declaration issued in connection with 
COVID–19 pursuant to section 319F–3 of the Pub-
lic Health Service Act (42 U.S.C. 247d–6d); and 
(2) not reissue any such declaration or any sub-
stantially similar declaration. 
(b) CORRESPONDING TERMINATION
OF LIABILITY 
PROTECTION.—No immunity from suit and liability under 
section 319F–3 of the Public Health Service Act (42 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS
U.S.C. 247d–6d) shall apply with respect to the adminis-
tration to or the use by an individual of a covered counter-
measure if— 
(1) the immunity relies on a declaration de-
scribed in subsection (a); and 
(2) the administration or use occurs after such 
declaration is terminated, 
except that the Secretary of Health and Human Services, 
pursuant to section 319F–3(b)(3)(B) of such Act (42 
U.S.C. 247d–6d(b)(3)(B)), shall specify an additional im-
munity period of 3 months for the manufacturer to ar-
range for disposition of the covered countermeasure and 
for covered persons to take such other actions as may be 
appropriate to limit administration or use of the covered 
countermeasure, as described in clauses (i) and (ii) of such 
section 319F–3(b)(3)(B). 
Æ 
VerDate Sep 11 2014 
16:42 Apr 04, 2022
Jkt 029200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6301
E:\BILLS\H7308.IH
H7308
pamtmann on DSKBC07HB2PROD with BILLS